# Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

> **NCT06327815** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 633 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
- **DRUG:** Dapagliflozin tablets and Metformin HCl extended-release tablets

## Key facts

- **NCT ID:** NCT06327815
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 633 (ACTUAL)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06327815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06327815, "Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06327815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*